Evotec SE and Alpine Immune Sciences said that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. The contract is a continuation of their first-in-human program ini...